Research Article

Investigation of the Effects of Metformin and Ifosfamide Applications on Cell Proliferation and Apoptosis in Hepatocellular Carcinoma Cells

Volume: 3 Number: 1 July 23, 2024
EN

Investigation of the Effects of Metformin and Ifosfamide Applications on Cell Proliferation and Apoptosis in Hepatocellular Carcinoma Cells

Abstract

Cancer is a concern, for health ranking as the second leading cause of death after cardiovascular diseases. Among types of cancers hepatocellular carcinoma (HCC) is particularly noteworthy being the most common type following lung and stomach cancers. Various treatment approaches are used for managing HCC like chemotherapy. In this study the HepG2 cancer cell line was used as a model to investigate the effects of ifosfamide and metformin on cancer cells. Cell viability tests and RT PCR analysis targeting genes associated with the PI3K/AKT/mTOR pathway were conducted to evaluate these effects. These results offer valuable insights for advancing further research for their potential application in the treatment not only of HCC but also of other cancer types.

Keywords

Hepatocellular Cancer , Metformin , Ifosfamide , Cell Proliferation , PI3K/AKT/mTOR pathway

References

  1. 1. Huang DQ, Singal AG, Kanwal F, Lampertico P, Buti M, Sirlin CB, Nguyen MH and Loomba R. Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology. Nature Reviews Gastroenterology & Hepatology. 2023; 20;797-809.
  2. 2. Chidambaranathan – Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Advances in Cancer Research. 2021;149;1-61.
  3. 3. Brown ZJ, Tsilimigras DI, Ruff SM. Management of Hepatocellular Carcinoma. JAMA Surgery. 2023;158;4;410-420.
  4. 4. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73;51;4-13.
  5. 5. Behranvand N, Nasri F, Emameh RZ, Khani P, Hosseini A, Garssen J and Falak R. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunology, Immunotherapy. 2022;71;507-526.
  6. 6. Idle JR, Beyoğlu D. Ifosfamide - History, efficacy, toxicity and encephalopathy. Pharmacology & Therapeutics. 2023;243;108366.
  7. 7. Ugwueze CV, Ogamba OZ, Young EE, Onyenekwe BM and Ezeokpo BC. Metformin: A Possible Option in Cancer Chemotherapy. Analytical Cellular Pathology. 2020.
  8. 8. Rizos CV, Elisaf MS. Metformin and cancer. European Journal of Pharmacology. 2013;705;1;3;96-108.
  9. 9. Winston CA, Jiang AA, Shuen Toh EM, Han C, Ong ZH, Peng S, Tham HY, Sundar R, Chong CS and Khoo CM. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. International Journal of Colorectal Disease. 2020;35;1501-1512.
  10. 10. Özakyol A. Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). Journal of Gastrointestinal Cancer. 2017;48;238-240.
APA
Güney, B. N., Topal Kızıloğlu, H., Solak, K., Ulusoy, D., & Kara, A. (2024). Investigation of the Effects of Metformin and Ifosfamide Applications on Cell Proliferation and Apoptosis in Hepatocellular Carcinoma Cells. Eurasian Journal of Molecular and Biochemical Sciences, 3(1), 17-24. https://izlik.org/JA73LA58JG